Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular safety trial of oral semaglutide in type 2 diabetes
2015-003563-10Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide with Placebo (2 arms). Primary endpoint: Major adverse cardiovascular event composite. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-003563-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003563-10.